Crescent Biopharma, Inc. Common StockCBIO
About: Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
0.58% more ownership
Funds ownership: 47.07% [Q4 2024] → 47.66% (+0.58%) [Q1 2025]
15% less capital invested
Capital invested by funds: $7.56M [Q4 2024] → $6.46M (-$1.1M) [Q1 2025]
17% less funds holding
Funds holding: 41 [Q4 2024] → 34 (-7) [Q1 2025]
29% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 7
50% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 12
54% less call options, than puts
Call options by funds: $24K | Put options by funds: $52K
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Stifel Stephen Willey | 116%upside $28 | Buy Initiated | 25 Jun 2025 |
LifeSci Capital Charles Zhu | 70%upside $22 | Outperform Initiated | 18 Jun 2025 |
Financial journalist opinion

